|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 2 (July 15), 1997:
pp. 562-570
RAPID COMMUNICATION
Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines
By
Andrea König,
Laura Wrazel,
Raymond P. Warrell Jr,
Roberta Rivi,
Pier Paolo Pandolfi,
Ann Jakubowski, and
Janice L. Gabrilove
From The Molecular Therapeutics Program, the Sloan-Kettering Institute, the Department of Medicine, Division of Hematology-Oncology, and the Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY.
 |
ABSTRACT |
Inorganic arsenic trioxide (As2O3 ) was recently shown to induce apoptosis in NB4 promyelocytic leukemic cells. We have investigated the effects of the organic arsenical, melarsoprol (a drug used for treatment of trypanosomiasis), upon induction of apoptosis in cell lines representative of chronic B-cell lymphoproliferative disorders. An Epstein-Barr virus (EBV)-transformed B-prolymphocytic cell line (JVM-2), an EBV-transformed B-cell chronic lymphocytic leukemia (B-CLL) cell line (I83CLL), and one non-EBV-transformed B-CLL cell line (WSU-CLL) were used as targets. Dose-response experiments with melarsoprol (10-7 to 10-9 mol/L) were performed over 96 hours. Unexpectedly, we found that melarsoprol caused a dose- and time-dependent inhibition of survival and growth in all three cell lines. In contrast, As2O3 at similar concentrations had no effect on either viability or growth. After 24 hours, all three cell lines treated with melarsoprol (10-7 mol/L) exhibited morphologic characteristics of apoptosis. We also observed prominent concentration-dependent downregulation of bcl-2 mRNA after 24 hours of exposure to melarsoprol in WSU-CLL, I83CLL, and JVM-2 cells. Decrease of bcl-2 protein expression was also observed in all three cell lines, whereas As2O3 had no effect on this parameter. We conclude that melarsoprol may inhibit the growth of lymphoid leukemic cell by promoting programmed cell death. Results of these studies suggest that melarsoprol shows promising therapeutic activity in these diseases, and a study to evaluate clinical effects of this drug has been initiated.
| |
INTRODUCTION |
ARSENIC-CONTAINING compounds have been used as cancer treatment for hundreds of years.1-3 Inorganic potassium arsenite (Fowler's solution) was used to control elevated leukocyte counts in chronic myelogenous leukemia in the early 1900s.2,3 With the advent of x-ray therapy and conventional cytotoxic drugs, the use of arsenicals for cancer treatment in Western countries has been abandoned. However, in traditional Asian folk medicine, arsenicals are still used for this purpose.
Arsenic trioxide (As2O3 ) was recently reported to induce complete remission in a high proportion of patients with refractory acute promyelocytic leukemia (APL).4 More recently, in vitro studies in NB4 cells showed that As2O3 induced apoptosis5 that was associated with a downregulation of bcl-2. The only arsenical currently formulated for human use in Western countries is melarsoprol, which is an organic arsenic compound synthesized by complexing melarsen oxide with the metal-chelating drug, dimercaprol.6 This agent has been used to treat African trypanosomiasis since the 1950s.7
Chronic lymphocytic leukemia (CLL), the most frequent type of adult leukemia in Western countries, is a chronic lymphoproliferative disorder characterized by the progressive accumulation of clonally derived, CD5+, CD19+ B lymphocytes.8 It has been suggested that prolonged life span, due to dysregulation of apoptosis, is a major factor contributing to the delayed senescence of these transformed lymphocytes.9
We have investigated both melarsoprol and arsenic trioxide for its effects on various lymphoid cells.
In these studies, we unexpectedly found that melarsoprol, but not As2O3 , exhibited potent cytotoxic activity that was associated with downregulation of bcl-2 protein expression and induced apoptosis.
| |
MATERIALS AND METHODS |
Reagents.
Melarsoprol (kindly supplied as Arsobal [36 mg/mL] by Rhone Poulenc Rorer, Collegeville, PA) was further diluted in propylene glycol at a stock concentration of 10-4 mol/L and stored at room temperature. Serial dilutions (10-6 to 10-9 mol/L) were also made with propylene glycol. As2O3 (Sigma, St Louis, MO) was dissolved in 1.65 mol/L sodium hydroxide (NaOH) at a stock solution of 10-3 mol/L. Serial dilutions (10-6 to 10-9 mol/L) were made in RPMI 1640.
Cell lines.
The well-characterized permanent human B-cell leukemia cell line JVM-210,11 was established from the peripheral blood of a patient with B-prolymphocytic leukemia (PLL) by Epstein-Barr virus (EBV) immortalization. The human chronic B-cell leukemia cell line, I83CLL, was derived from the peripheral blood of a patient with B-cell chronic lymphocytic leukemia (B-CLL) by EBV immortalization.12 The human EBV-negative cell line, WSU-CLL (generously provided by Dr Ayad Al-Katib, Wayne State University School of Medicine, Detroit, MI), was established from a patient with advanced B-CLL.13 All three cell lines and the human promyelocytic cell line HL-60 (used as a positive control for bcl-2 expression) were cultured in RPMI 1640, supplemented with 1% penicillin/streptomycin, 1 mmol/L L-glutamine (GIBCO, Grand Island, NY), 10% heat-inactivated fetal bovine serum (FBS; GIBCO) at 37°C, 5% CO2 in air.
Patient samples.
Peripheral blood was drawn from patients with documented B-CLL after obtaining informed consent. B-CLL cells were separated by Ficoll-Hypaque centrifugation, washed three times in phosphate-buffered saline (PBS), and resuspended in RPMI 1640 supplemented with 10% FBS, 1% penicillin/streptomycin, and 1 mmol/L L-glutamine. A total of 3 × 105 cells/mL was used for viability experiments, which were incubated with or without melarsoprol (0.5 × 10-6 to 10-9 mol/L) or arsenic trioxide (10-6 to 10-9 mol/L) for 24 to 96 hours at 37°C, 5% CO2 in air.
View larger version (33K):
[in this window]
[in a new window]
| Fig 1.
Effect of melarsoprol on the viability (A, C, and E) and cell growth (B, D, and F ) of B-CLL cell lines at various concentrations of melarsoprol for 96 hours. Control cells were cultured in the presence of polyethylene glycol alone (PG CTRL).
|
|
View larger version (32K):
[in this window]
[in a new window]
| Fig 2.
Effect of As2O3 on the viability (A, C, and E) and cell growth (B, D, and F ) of B-CLL cell lines at various concentrations of As2O3 for 96 hours. Control cells were cultured in the presence of the highest NaOH concentration used for dilutions of As2O3 (NaOH CTRL).
|
|
View larger version (142K):
[in this window]
[in a new window]
| Fig 3.
Morphologic changes showing features of apoptosis in B-CLL cell lines after treatment with melarsoprol for 24 hours (original magnification × 600). (A) Untreated WSU-CLL cells; (B) 10-8 mol/L melarsoprol-treated WSU-CLL cells; (C) untreated I83CLL cells; (D) 10-8 mol/L melarsoprol-treated I83CLL cells; (E) untreated JVM-2 cells; (F ) 10-8 mol/L melarsoprol-treated JVM-2 cells. The cells were stained using Giemsa-Wright stain.
|
|
Viability and cell growth.
Cell viability and growth were assessed by trypan blue (GIBCO) exclusion using a hemocytometer. Samples were collected and each sample was evaluated in triplicate.
Cell morphology.
Using cellular and nuclear morphology, specific changes in DNA organization and cytoplasmic integrity, including membrane blebbing, cellular shrinkage, chromatin condensation, and fragmentation, were examined. For differential staining, cytocentrifuge preparations were stained using Wright-Giemsa stain (Diff Quick; Baxter, Miami, FL)
RNA isolation.
Cells were lysed with 0.2 mL of RNAzolTMB (Tel-Test, Friendswood, TX) per 106 cells. Chloroform (0.2 mL/2 mL of lysate) was added to the samples; after vortexing, the suspension was incubated on ice for 5 minutes, followed by centrifugation at 12,000g at 4°C for 15 minutes. The aqueous phase was then transferred into a fresh tube and an equal volume of isopropanol was added. Samples were kept on ice for 60 minutes and centrifuged at 12,000g at 4°C for 15 minutes. The pellets were washed with 75% ethanol, dried, and resuspended in H2O. RNA concentration was determined by spectrophotometer at 260 nm.
Nonradioactive Northern blot analysis.
Total cellular RNA (10 µg/lane) was size-fractionated by electrophoresis in a 1.2% agarose gel containing 0.7 mol/L formaldehyde, transferred to nylon membranes (Hybond N; Amersham, Arlington Heights, IL) by capillary suction overnight, and cross-linked by UV light (Stratalinker; Stratagene, La Jolla, CA). The cDNA probe for bcl-2, a 410-bp EcoRI fragment in pCR II vector (TA cloning vector; Invitrogen, San Diego, CA) digested with BamHI, was labeled with digoxygenin-UTP (DIG-UTP; Boehringer Mannheim, Indianapolis, IN) by in vitro transcription with respect to T7 RNA-polymerase. The cDNA probe for glyceraldehyde phosphate dehydrogenase (GAPDH), a 1,270-bp insert in pBS KS+ (ATCC), was linearized with EcoRI and labeled with DIG-UTP by in vitro transcription with respect to T7 RNA-polymerase. Hybridization was performed as previously described.14 Detection was accomplished by chemiluminescent reaction according to the Genius System (Boehringer Mannheim), as previously described.14
In situ deoxynucleotidyl transferase (TdT) assay.
The in situ TdT assay was performed as previously described.14,15 Briefly, aliquots of cells were collected from liquid culture, centrifuged, and fixed in 0.3% buffered formaldehyde (pH 7.5). After washing with PBS, cells were resuspended in 70% ethanol (-20°C) and stored at -20°C. After rehydration with PBS, the cells were resuspended in 50 µL cacodylate buffer containing 0.2 mol/L potassium cacodylate, 2.5 mmol/L Tris-HCl (pH 6.6), 2.5 mmol/L cobalt chloride (CoCl2 ), 0.25 mg/mL bovine serum albumin (BSA), 7.5 U TdT, and 0.5 nmol/L biotinylated deoxyuracil-triphosphphate (b-dUTP; all reagents from Boehringer Mannheim). After an incubation period in this solution for 30 minutes at 37°C, cells were washed with PBS and resuspended in 100 mL of a solution containing 4× SSC, 25 µg/mL avidin-fluorescein-isothiocyanate (avidin-FITC; Boehringer Mannheim), 0.1% Triton X-100, and 5% wt/vol nonfat dry milk and incubated for 30 minutes in the dark at room temperature. Cells were washed with PBS containing 0.1% Triton X-100 and resuspended in 0.5 mL PBS containing 5 µg/mL propidium iodide (Sigma) and 0.1% RNAse A (Sigma). Green fluorescence detecting FITC levels and red fluorescence measuring propidium iodide content of individual cells were quantified on a FACStar (Becton Dickinson, Franklin Lakes, NJ). Data from 2 × 104 cells were collected and used for analysis.
Western blot analysis.
Cells were lysed in a lysis buffer containing 20 mmol/L Tris-HCl, 1 mmol/L EGTA, 50 mmol/L NaVO4 , 50 mmol/L NaF, 0.01 U/mL aprotinin, 10 µg/mL leupeptin, 10 µg/mL pepstatin, 1 mmol/L elastinal, and 1 µmol/L phenylmethylsulfonyl fluoride (PMSF; all Sigma). The lysates were then sonicated using a ultrasonic homogenizer (4710 series; Cole Parmer Instruments, Chicago, IL) and centrifuged at 7,500g in a microfuge (Sorvall Instruments, Wilmington, DE), and the protein content of the lysates was determined (BioRad Protein Assay Kit I; BioRad, Melville, NY) at 595 nm with a BSA standard. Sample buffer containing 10% glycerol, 0.4% sodium dodecyl sulfate (SDS), 0.3% bromphenol blue, and 0.2% pyronin Y in 1× stacking buffer (Tris base 0.5 mol/L, 0.8% SDS) and 20% 2-mercaptoethanol was added to the cell lysates, which subsequently were heat-denaturated at 95°C for 3 minutes. Protein (10 µg/lane) was loaded on an SDS-polyacrylamide gel containing 12.5% polyacrylamide and size-fractionated by electrophoresis. Proteins were electroblotted onto Immobilon-P PVDF transfer membrane (Millipore, Bedford, MA) and immunostained with a mouse antihuman monoclonal bcl-2 antibody (1:5,000; Dako, Carpinteria, CA). Bound antibody was detected using the ECL chemiluminescence detection system (Amersham). Protein bands were quantified by computer densitometry.
| |
RESULTS |
Melarsoprol decreases viability and arrests cell growth in CLL cell lines.
To investigate the potential effect of melarsoprol and As2O3 , respectively, on cell growth and survival, I83CLL, JVM-2, and WSU-CLL cells were used as targets. Treatment of the cells with melarsoprol (10-7 to 10-9 mol/L) over a time period of 96 hours led to a marked dose- and time-dependent inhibition of cell survival (Fig 1A through C) as determined using trypan blue exclusion. Exposure of the cell lines to 10-7 mol/L (WSU-CLL, I83CLL, and JVM-2) and 10 -8 mol/L (I83CLL and JVM-2) melarsoprol resulted in a significant decrease in cell viability, whereas lower concentrations (10-9 mol/L in I83CLL and JVM-2; 10-8 mol/L and 10-9 mol/L in WSU-CLL) were ineffective (Fig 1A through C).
View larger version (40K):
[in this window]
[in a new window]
| Fig 4.
Detection of apoptosis-associated DNA strand-breaks by in situ TdT assay in WSU-CLL cells. The cells were either untreated (CTRL) or exposed to melarsoprol for 24 and 48 hours, respectively. The dots represent the distribution of individual cells with respect to their b-dUTP incorporation and DNA content. The degree of b-dUTP complexes correlated with DNA strand-breaks per cell.
|
|
View larger version (27K):
[in this window]
[in a new window]
| Fig 6.
Regulation of bcl-2 protein expression in I83CLL and WSU-CLL cells after treatment with melarsoprol. Cells (1 × 106/mL) were cultured alone (CTRL) or in the presence of melarsoprol for 24 hours.
|
|
Exposure of the cells to melarsoprol also led to a marked dose- and time-dependent inhibition of cell growth. Treatment of the cells with the organic arsenical resulted in a 50% growth inhibitory concentration (IC50 ) of 10-7 and 10-8 mol/L in all three cell lines after 24 hours. Lower concentrations (10-9 mol/L) did not result in a growth arrest (Fig 1D through F ).
In contrast, exposure of all three cell lines to inorganic As2O3 at the same concentrations (10-7 to 10-9 mol/L) had no effect on the survival (Fig 2A through C) or growth of these cell lines (Fig 2D through F ).
Morphologic changes characteristic of apoptosis.
Morphologic analysis showed characteristic apoptotic changes, such as chromatin condensation and fragmentation, membrane blebbing, and formation of apoptotic bodies, in all three cell line targets in a concentration-dependent manner after treatment with melarsoprol (10-7 to 10-9 mol/L; Fig 3)
Induction of apoptosis-related DNA strand-breaks by melarsoprol.
WSU-CLL cells were treated with melarsoprol and examined for apoptosis-associated DNA strand breaks using the TdT assay. The intensity of labeling of apoptotic cells with biotinylated dUTP correlated with the number of DNA strand breaks per cell. The data showed that a significant number of cells exposed to the arsenical compound underwent apoptosis. Treatment of WSU-CLL cells with melarsoprol (10-8 mol/L) for 24 hours promoted apoptosis in 23.5% of the treated cells versus control cells, which exhibited 0.9% apoptosis. After 48 hours of incubation with melarsoprol, 85% of the cells were apoptotic, compared with untreated cells with 2.1% apoptosis (Fig 4).
Regulation of bcl-2 expression by melarsoprol.
We next examined the expression of bcl-2 mRNA and protein in I83CLL, JVM-2, and WSU-CLL cells after exposure to either the organic or the inorganic arsenical. Northern blot analysis showed a total loss of bcl-2 mRNA expression in I83CLL and WSU-CLL cells after 24 hours of incubation with 10-7 and 10-8 mol/L (Fig 5A). Melarsoprol concentrations as low as 10-9 mol/L still induced a significant decrease of bcl-2 transcripts. Similar effects were observed in JVM-2 cells (data not shown).
A dose-dependent response was also observed at the protein level. After 24 hours, bcl-2 protein expression was markedly reduced after incubation with 10-7 and 10-8 mol/L melarsoprol as compared with the expression of protein from untreated cells. A concentration of 10-9 mol/L had no effect at this time point (Fig 6). By contrast, no changes in bcl-2 expression were observed at either the mRNA (Fig 5B) or protein level (data not shown) after exposure to As2O3.
Melarsoprol decreases viability and cell growth in fresh CLL lymphocytes.
Treatment of lymphocytes from five B-CLL patients of various clinical stages with melarsoprol (0.5-6 to 10-9 mol/L) resulted in a dose- and time-dependent decrease of viability (Table 1) and cell growth (not shown). In contrast, comparable concentrations of As2O3 (10-6 to 10-9 mol/L) generally had no effect on the growth or viability of freshly isolated cells from patients with B-CLL; however, a decline in viability to 48% (Table 2) and cell number (not shown) was noted with 10-6 mol/L As2O3 after 96 hours of exposure in one patient`s sample (patient no. 4).
| |
DISCUSSION |
Recently, As2O3 , an inorganic arsenic compound, was found to induce apoptosis in NB4 APL cells,5,16 possibly by decreasing expression of bcl-2 mRNA and protein.5 Recently, clinical studies in China have shown that As2O3 treatment is an effective drug in patients with APL.17 Given As2O3's lack of clinical availability in the West, we compared the effects of As2O3 with melarsoprol, an organic arsenical that has been well characterized as a treatment of late hemolymphatic and central nervous system African trypanosomiasis.7 Preliminary in vitro results by our group have suggested that this agent has broad efficacy against leukemic cell lines of both lymphoid and myeloid lineage.18 In all cell lines that responded to the drug, induction of apoptosis appeared to be a common feature. In trypanosomiasis, melarsoprol reversibly inhibits the cellular enzymes glutathione reductase and NADPH oxidase.19,20 Cellular resistance to the drug appears be mediated by the ars operon, which encodes repressor proteins that reduce arsenate to arsenite.21
In this study, we showed that melarsoprol unexpectedly reduced the growth and survival of cells that are characteristic of B-cell chronic lymphoid malignancies by triggering programmed cell death (apoptosis). These effects were associated with a dramatic decrease/loss of bcl-2 proto-oncogene expression, as observed at both mRNA and protein levels. By contrast, As2O3 has no major effect on viability or cell growth of these lymphoid cell lines or on the expression of apoptosis-related genes such as bcl-2 at in vivo pharmacologic concentrations ranging from 10-7 to 10-9 mol/L. Moreover, As2O3 did not significantly affect either the growth or viability of malignant lymphoid cells freshly isolated from patients with B-CLL. Because As2O3 had no effect on growth, survival, or apoptosis induction in other leukemic cell lines (U937 and HL-60),5 Chen et al5 suggested that this specific arsenical might be restricted to be a selective inducer of apoptosis in APL.5 However, our data using As2O3 in other myeloid leukemic cell lines do not confirm this speculation regarding such high selectivity.18
Apoptosis occurs during senescence of normal cells, and dysregulation of apoptosis may play a crucial role in the development of CLL.21-25 Altered expression of other gene products may also critically affect this process, including deletions of the retinoblastoma (RB) gene,26 p53 mutations,27 and overexpression of cyclin D2.28 Although bcl-2 gene rearrangement occurs infrequently in CLL, elevated levels of bcl-2 have been documented in most B-CLL cells.29 Thus, it is of particular interest that melarsoprol could induce apoptosis in cell lines derived from patients with this disease and in freshly isolated lymphocytes from B-CLL patients. As suggested by recent studies of As2O3 in NB4 cells, one mechanism by which melarsoprol may act is by regulating genes such as bcl-2 that are involved in this process. Whether bcl-2 selectively targeted by melarsoprol seems unlikely, and further investigations are underway to elucidate these additional mechanisms.
We conclude that melarsoprol appears be a potent inducer of programmed cell death in leukemic cell lines representative of chronic lymphoid cancers. Based on the data and related studies,18 we have initiated a clinical investigation broadly directed against both acute and chronic myeloid and lymphoid leukemias with this agent.30
| |
FOOTNOTES |
Submitted March 6, 1997;
accepted May 7, 1997.
Supported by grants from the Deutsche Forschungsgemeinschaft (Ko 1583/1-1) and the American Cancer Society (DHP-82).
Address correspondence to Andrea König, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, PO Box 320, New York, NY 10021.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
REFERENCES |
1. Bainbridge WS: the Cancer Problem. New York, NY, Macmillan, 1914, p 271
2.
Forkner C,
McNair-Scott TF:
Arsenic as a therapeutic agent in chronic myeloid leukemia.
JAMA
97:305,
1931
3.
Kandel EV,
Leroy GV:
Chronic arsenical poisening during the treatment of chronic myeloid leukemia.
Arch Intern Med
60:846,
1937[Abstract/Free Full Text]
4.
Sun HD,
Ma L,
Hu XL,
Zhang TD:
Ai-Lin I treated 32 cases of acute promyelocytic leukemia.
Chin J Intergrat Chin Western Med
12:170,
1992
5.
Chen GQ,
Zhu J,
Shi XG,
Ni JH,
Zhong HJ,
Si GY,
Jin XL,
Tang W,
Li XS,
Xong SM,
Shen ZX,
Sun GL,
Ma J,
Zhang P,
Zhang TD,
Gazin C,
Naoe T,
Chen SJ,
Wang ZY,
Chen Z:
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3 ) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
Blood
88:1052,
1996[Abstract/Free Full Text]
6.
Ercoli N,
Wilson W:
Influence of BAL on the toxicity and chemotherapeutic activity of marpharsen.
J Pharmacol Exp Therapeutics
92:121,
1948[Abstract/Free Full Text]
7.
Friedheim EAH:
The active form of tryparsamide TPB in the treatment of human trypanosomiasis.
Am J Trop Med
29:173,
1949[Medline]
[Order article via Infotrieve]
8.
Dighiero G,
Travade P,
Chevret S,
Fenaux P,
Chastang C,
Binet JL:
B-cell chronic lymphocytic leukemia: Present status and future directions. French Cooperative Group on CLL (Review).
Blood
78:1901,
1991[Free Full Text]
9.
Cheson B,
Bennet J,
Rai K,
Grever M,
Kay N,
Schiffer C,
Oken M,
Keating M,
Boldt B,
Kempin S,
Foon K:
Guidelines for the classsification of chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group.
Am J Hematol
29:152,
1988[Medline]
[Order article via Infotrieve]
10.
Melo JV,
Brito-Babapulle V,
Foroni L,
Robinson DS,
Luzzatto L,
Catovsky D:
Two new cell lines from B-prolymphocytic leukaemia: Characterization by morphology, immunological markers, karyotype and Ig gene rearrangement.
Intern J Cancer
38:531,
1986[Medline]
[Order article via Infotrieve]
11.
Melo JV,
Foroni L,
Brito-Babapulle V,
Luzzatto L,
Catovsky D:
The establishment of cell lines from chronic B cell leukaemias: Evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement.
Clin Exp Immunol
73:23,
1988[Medline]
[Order article via Infotrieve]
12.
Wendel-Hansen V,
Sallstrom J,
De Campos-Lima PO,
Kjellstrom G,
Sandlund A,
Siegbahn A,
Carlsson M,
Nilsson K,
Rosen A:
Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines.
Leukemia
8:476,
1994[Medline]
[Order article via Infotrieve]
13.
Mohammad RM,
Mohamed AN,
Hamdan MY,
Vo T,
Chen B,
Katato K,
Abubakr YA,
Dugan MC,
al-Katib A:
Establishment of a human B-CLL xenograft model: Utility as a preclinical therapeutic model.
Leukemia
10:130,
1996[Medline]
[Order article via Infotrieve]
14.
König A,
Menzel T,
Lynen S,
Wrazel L,
al-Katib A,
Rosen A,
Raveche E,
Gabrilove JL:
Basic fibroblast growth factor (bFGF ) upregulates the expression of bcl-2 in chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.
Leukemia
11:258,
1997[Medline]
[Order article via Infotrieve]
15.
Gorczyca W,
Gong J,
Ardelt B,
Traganos F,
Darzynkiewicz Z:
The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents.
Cancer Res
53:3186,
1993[Abstract/Free Full Text]
16.
Chen G-Q,
Shi X-G,
Tang W,
Xiong S-M,
Zhu J,
Cai X,
Han Z-G,
Ni J-H,
Shi G-Y,
Jia P-M,
Liu M-M,
He K-L,
Niu C,
Ma J,
Zhang P,
Zhang T-D,
Paul P,
Naoe T,
Kitamura K,
Miller W,
Waxman S,
Wang Z-Y,
de The H,
Chen S-J,
Chen Z:
Use of arsenic trioxide (As2O3 ) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Blood
89:3345,
1997[Abstract/Free Full Text]
17.
Chen Z-X,
Chen G-Q,
Ni J-H,
Li X-S,
Xiong S-M,
Qiu Q-Y,
Zhu J,
Tang W,
Sun G-L,
Yang K-Q,
Chen Y,
Zhou L,
Fang Z-W,
Wang Y-T,
Ma J,
Zhang P,
Zhang T-D,
Chen S-J,
Chen Z,
Wang Z-Y:
Use of arsenic trioxide (As2O3 ) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Blood
89:3354,
1997[Abstract/Free Full Text]
18. Rivi R, Calleja E, König A, Lai L, Gambacorti-Passerini C, Scheinberg D, Gabrilove JL, Warrell RP Jr, Pandolfi PP: Organic arsenical melarsoprol shows growth suppressive activity via programmed cell death on APL and other myeloid and lymphoid leukemia derived cell lines. Blood 88:68a, 1996 (abstr, suppl 1)
19.
Muller S,
Walter RD,
Fairlamb AH:
Differential susceptibility of filarial and human erythrocyte glutathione reductase to inhibition by the trivalent organic arsenical melarsen oxide.
Mol Biochem Parasitol
71:211,
1995[Medline]
[Order article via Infotrieve]
20.
Le Cabec V,
Maridonneau-Parini I:
Complete and reversible inhibition of NADPH oxidase in human neutrophils by phenylarsine oxide at a step distal to membrane translocation of the enzyme subunits.
J Biol Chem
270:2067,
1995[Abstract/Free Full Text]
21.
Rosen BP,
Bhattacharjee H,
Shi W:
Mechanisms of metalloregulation of an anion-translocating ATPase (review).
J Bioenergetics Biomembranes
27:85,
1995[Medline]
[Order article via Infotrieve]
22.
Robertson LE,
Chubb S,
Meyn RE,
Story M,
Ford R,
Hittelman WN,
Plunkett W:
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Blood
81:143,
1993[Abstract/Free Full Text]
23.
Dancescu M,
Rubio-Trujillo M,
Biron G,
Bron D,
Delespesse G,
Sarfati M:
Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.
J Exp Med
176:1319,
1992[Abstract/Free Full Text]
24.
McConkey DJ,
Hartzell P,
Jondal M,
Orrenius S:
Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C.
J Biol Chem
264:13399,
1989[Abstract/Free Full Text]
25.
Hoffbrand AV,
Panayiotidis P,
Reittie J,
Ganeshaguru K:
Autocrine and paracrine growth loops in chronic lymphocytic leukemia (review).
Semin Hematol
30:306,
1993[Medline]
[Order article via Infotrieve]
26.
Liu Y,
Grander D,
Soderhall S,
Juliusson G,
Gahrton G,
Einhorn S:
Retinoblastoma gene deletions in B-cell chronic lymphocytic leukemia.
Genes Chromosom Cancer
4:250,
1992[Medline]
[Order article via Infotrieve]
27.
Fenaux P,
Preudhomme C,
Lai JL,
Quiquandon I,
Jonveaux P,
Vanrumbeke M,
Sartiaux C,
Morel P,
Loucheux-Lefebvre MH,
Bauters F,
Berger R,
Kerchaert JP:
Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: A report on 39 cases with cytogenetic analysis.
Leukemia
6:246,
1992[Medline]
[Order article via Infotrieve]
28.
Delmer A,
Ajchenbaum-Cymbalista F,
Tang R,
Ramond S,
Faussat AM,
Marie JP,
Zittoun R:
Overexpression of cyclin D2 in chronic B-cell malignancies.
Blood
85:2870,
1995[Abstract/Free Full Text]
29.
Hanada M,
Delia D,
Aiello A,
Stadtmauer E,
Reed JC:
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.
Blood
82:1820,
1993[Abstract/Free Full Text]
30. Soignet S, Rivi R, Tong WP, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr: Clinical and laboratory studies in leukemia of an organic arsenical, melarsoprol. Proc Am Soc Clin Oncol 16:4a, 1997 (abstr)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Ying, K. Myers, S. Bottomley, T. Helleday, and H. E. Bryant
BRCA2-dependent homologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells
Nucleic Acids Res.,
August 1, 2009;
37(15):
5105 - 5113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tun-Kyi, J. -Z. Qin, P. A. Oberholzer, A. A. Navarini, J. C. Hassel, R. Dummer, and U. Dobbeling
Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model
Ann. Onc.,
August 1, 2008;
19(8):
1488 - 1494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-Y. Chai, Y.-C. Huang, W.-C. Hung, W.-Y. Kang, and W.-T. Chen
Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells
Mutagenesis,
November 1, 2007;
22(6):
403 - 408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chen, R. Chan, S. Waxman, and Y. Jing
Buthionine Sulfoximine Enhancement of Arsenic Trioxide-Induced Apoptosis in Leukemia and Lymphoma Cells Is Mediated via Activation of c-Jun NH2-Terminal Kinase and Up-regulation of Death Receptors
Cancer Res.,
December 1, 2006;
66(23):
11416 - 11423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Giafis, E. Katsoulidis, A. Sassano, M. S. Tallman, L. S. Higgins, A. R. Nebreda, R. J. Davis, and L. C. Platanias
Role of the p38 Mitogen-Activated Protein Kinase Pathway in the Generation of Arsenic Trioxide-Dependent Cellular Responses.
Cancer Res.,
July 1, 2006;
66(13):
6763 - 6771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Douer and M. S. Tallman
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
J. Clin. Oncol.,
April 1, 2005;
23(10):
2396 - 2410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Diaz, M. Colombo, K. K. Mann, H. Su, K. N. Smith, D. S. Bohle, H. M. Schipper, and W. H. Miller Jr
Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines
Blood,
February 1, 2005;
105(3):
1237 - 1245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ferry-Dumazet, O. Garnier, M. Mamani-Matsuda, J. Vercauteren, F. Belloc, C. Billiard, M. Dupouy, D. Thiolat, J. P. Kolb, G. Marit, et al.
Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells
Carcinogenesis,
August 1, 2002;
23(8):
1327 - 1333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hayashi, T. Hideshima, M. Akiyama, P. Richardson, R. L. Schlossman, D. Chauhan, N. C. Munshi, S. Waxman, and K. C. Anderson
Arsenic Trioxide Inhibits Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment
Mol. Cancer Ther.,
August 1, 2002;
1(10):
851 - 860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res.,
July 15, 2002;
62(14):
3893 - 3903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Slack, S. Waxman, G. Tricot, M. S. Tallman, and C. D. Bloomfield
Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide
Oncologist,
April 1, 2002;
7(90001):
1 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sordet, C. Rebe, I. Leroy, J.-M. Bruey, C. Garrido, C. Miguet, G. Lizard, S. Plenchette, L. Corcos, and E. Solary
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis
Blood,
June 15, 2001;
97(12):
3931 - 3940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Waxman and K. C. Anderson
History of the Development of Arsenic Derivatives in Cancer Therapy
Oncologist,
April 1, 2001;
6(90002):
3 - 10.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. J. Murgo
Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
Oncologist,
April 1, 2001;
6(90002):
22 - 28.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. J. Roboz, S. Dias, G. Lam, W. J. Lane, S. L. Soignet, R. P. Warrell Jr, and S. Rafii
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
Blood,
August 15, 2000;
96(4):
1525 - 1530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sgadari, E. Toschi, C. Palladino, G. Barillari, D. Carlei, A. Cereseto, C. Ciccolella, R. Yarchoan, P. Monini, M. Sturzl, et al.
Mechanism of Paclitaxel Activity in Kaposi's Sarcoma
J. Immunol.,
July 1, 2000;
165(1):
509 - 517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Park, J. G. Seol, E. S. Kim, J. M. Hyun, C. W. Jung, C. C. Lee, B. K. Kim, and Y. Y. Lee
Arsenic Trioxide-mediated Growth Inhibition in MC/CAR Myeloma Cells via Cell Cycle Arrest in Association with Induction of Cyclin-dependent Kinase Inhibitor, p21, and Apoptosis
Cancer Res.,
June 1, 2000;
60(11):
3065 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Perkins, C. N. Kim, G. Fang, and K. N. Bhalla
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL
Blood,
February 1, 2000;
95(3):
1014 - 1022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Estrov, S. K. Manna, D. Harris, Q. Van, E. H. Estey, H. M. Kantarjian, M. Talpaz, and B. B. Aggarwal
Phenylarsine Oxide Blocks Interleukin-1beta -Induced Activation of the Nuclear Transcription Factor NF-kappa B, Inhibits Proliferation, and Induces Apoptosis of Acute Myelogenous Leukemia Cells
Blood,
October 15, 1999;
94(8):
2844 - 2853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Huang, W.-y. Ma, J. Li, and Z. Dong
Arsenic Induces Apoptosis through a c-Jun NH2-Terminal Kinase-dependent, p53-independent Pathway
Cancer Res.,
July 1, 1999;
59(13):
3053 - 3058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-R. Gurr, D.-T. Bau, F. Liu, S. Lynn, and K.-Y. Jan
Dithiothreitol Enhances Arsenic Trioxide-Induced Apoptosis in NB4 Cells
Mol. Pharmacol.,
July 1, 1999;
56(1):
102 - 109.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Melnick and J. D. Licht
Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
Blood,
May 15, 1999;
93(10):
3167 - 3215.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-H. Zhu, Y.-L. Shen, Y.-k. Jing, X. Cai, P.-M. Jia, Y. Huang, W. Tang, G.-Y. Shi, Y.-P. Sun, J. Dai, et al.
Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations
J Natl Cancer Inst,
May 5, 1999;
91(9):
772 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rousselot, S. Labaume, J.-P. Marolleau, J. Larghero, M.-H. Noguera, J.-C. Brouet, and J.-P. Fermand
Arsenic Trioxide and Melarsoprol Induce Apoptosis in Plasma Cell Lines and in Plasma Cells from Myeloma Patients
Cancer Res.,
March 1, 1999;
59(5):
1041 - 1048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dai, R. S. Weinberg, S. Waxman, and Y. Jing
Malignant Cells Can Be Sensitized to Undergo Growth Inhibition and Apoptosis by Arsenic Trioxide Through Modulation of the Glutathione Redox System
Blood,
January 1, 1999;
93(1):
268 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Soignet, P. Maslak, Z.-G. Wang, S. Jhanwar, E. Calleja, L. J. Dardashti, D. Corso, A. DeBlasio, J. Gabrilove, D. A. Scheinberg, et al.
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
N. Engl. J. Med.,
November 5, 1998;
339(19):
1341 - 1348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z.-G. Wang, R. Rivi, L. Delva, A. Konig, D. A. Scheinberg, C. Gambacorti-Passerini, J. L. Gabrilove, R. P. Warrell Jr, and P. P. Pandolfi
Arsenic Trioxide and Melarsoprol Induce Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-RARalpha Independent Manner
Blood,
September 1, 1998;
92(5):
1497 - 1504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract
